Cargando…
Muscle and serum myostatin expression in type 1 diabetes
Type 1 diabetes (T1D) has been reported to negatively affect the health of skeletal muscle, though the underlying mechanisms are unknown. Myostatin, a myokine whose increased expression is associated with muscle‐wasting diseases, has not been reported in humans with T1D but has been demonstrated to...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354085/ https://www.ncbi.nlm.nih.gov/pubmed/32652899 http://dx.doi.org/10.14814/phy2.14500 |
_version_ | 1783558011118157824 |
---|---|
author | Dial, Athan G. Monaco, Cynthia M. F. Grafham, Grace K. Romanova, Nadya Simpson, Jeremy A. Tarnopolsky, Mark A. Perry, Christopher G. R. Kalaitzoglou, Evangelia Hawke, Thomas J. |
author_facet | Dial, Athan G. Monaco, Cynthia M. F. Grafham, Grace K. Romanova, Nadya Simpson, Jeremy A. Tarnopolsky, Mark A. Perry, Christopher G. R. Kalaitzoglou, Evangelia Hawke, Thomas J. |
author_sort | Dial, Athan G. |
collection | PubMed |
description | Type 1 diabetes (T1D) has been reported to negatively affect the health of skeletal muscle, though the underlying mechanisms are unknown. Myostatin, a myokine whose increased expression is associated with muscle‐wasting diseases, has not been reported in humans with T1D but has been demonstrated to be elevated in preclinical diabetes models. Thus, the purpose of this study was to determine if there is an elevated expression of myostatin in the serum and skeletal muscle of persons with T1D compared to controls. Secondarily, we aimed to explore relationships between myostatin expression and clinically important metrics (e.g., HbA(1c), strength, lean mass) in women and men with (N = 31)/without T1D (N = 24) between 18 and 72 years old. Body composition, baseline strength, blood sample and vastus lateralis muscle biopsy were evaluated. Serum, but not muscle, myostatin expression was significantly elevated in those with T1D versus controls, and to a greater degree in T1D women than T1D men. Serum myostatin levels were not significantly associated with HbA(1c) nor disease duration. A significant correlation between serum myostatin expression and maximal voluntary contraction (MVC) and body fat mass was demonstrated in control subjects, but these correlations did not reach significance in those with T1D (MVC: R = 0.64 controls vs. R = 0.37 T1D; Body fat: R = −0.52 controls/R = −0.02 T1D). Collectively, serum myostatin was correlated with lean mass (R = 0.45), and while this trend was noted in both groups separately, neither reached statistical significance (R = 0.47 controls/R = 0.33 T1D). Overall, while those with T1D exhibited elevated serum myostatin levels (particularly females) myostatin expression was not correlated with clinically relevant metrics despite some of these relationships existing in controls (e.g., lean/fat mass). Future studies will be needed to fully understand the mechanisms underlying increased myostatin in T1D, with relationships to insulin dosing being particularly important to elucidate. |
format | Online Article Text |
id | pubmed-7354085 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-73540852020-07-17 Muscle and serum myostatin expression in type 1 diabetes Dial, Athan G. Monaco, Cynthia M. F. Grafham, Grace K. Romanova, Nadya Simpson, Jeremy A. Tarnopolsky, Mark A. Perry, Christopher G. R. Kalaitzoglou, Evangelia Hawke, Thomas J. Physiol Rep Original Research Type 1 diabetes (T1D) has been reported to negatively affect the health of skeletal muscle, though the underlying mechanisms are unknown. Myostatin, a myokine whose increased expression is associated with muscle‐wasting diseases, has not been reported in humans with T1D but has been demonstrated to be elevated in preclinical diabetes models. Thus, the purpose of this study was to determine if there is an elevated expression of myostatin in the serum and skeletal muscle of persons with T1D compared to controls. Secondarily, we aimed to explore relationships between myostatin expression and clinically important metrics (e.g., HbA(1c), strength, lean mass) in women and men with (N = 31)/without T1D (N = 24) between 18 and 72 years old. Body composition, baseline strength, blood sample and vastus lateralis muscle biopsy were evaluated. Serum, but not muscle, myostatin expression was significantly elevated in those with T1D versus controls, and to a greater degree in T1D women than T1D men. Serum myostatin levels were not significantly associated with HbA(1c) nor disease duration. A significant correlation between serum myostatin expression and maximal voluntary contraction (MVC) and body fat mass was demonstrated in control subjects, but these correlations did not reach significance in those with T1D (MVC: R = 0.64 controls vs. R = 0.37 T1D; Body fat: R = −0.52 controls/R = −0.02 T1D). Collectively, serum myostatin was correlated with lean mass (R = 0.45), and while this trend was noted in both groups separately, neither reached statistical significance (R = 0.47 controls/R = 0.33 T1D). Overall, while those with T1D exhibited elevated serum myostatin levels (particularly females) myostatin expression was not correlated with clinically relevant metrics despite some of these relationships existing in controls (e.g., lean/fat mass). Future studies will be needed to fully understand the mechanisms underlying increased myostatin in T1D, with relationships to insulin dosing being particularly important to elucidate. John Wiley and Sons Inc. 2020-07-11 /pmc/articles/PMC7354085/ /pubmed/32652899 http://dx.doi.org/10.14814/phy2.14500 Text en © 2020 The Authors. Physiological Reports published by Wiley Periodicals LLC on behalf of The Physiological Society and the American Physiological Society. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Research Dial, Athan G. Monaco, Cynthia M. F. Grafham, Grace K. Romanova, Nadya Simpson, Jeremy A. Tarnopolsky, Mark A. Perry, Christopher G. R. Kalaitzoglou, Evangelia Hawke, Thomas J. Muscle and serum myostatin expression in type 1 diabetes |
title | Muscle and serum myostatin expression in type 1 diabetes |
title_full | Muscle and serum myostatin expression in type 1 diabetes |
title_fullStr | Muscle and serum myostatin expression in type 1 diabetes |
title_full_unstemmed | Muscle and serum myostatin expression in type 1 diabetes |
title_short | Muscle and serum myostatin expression in type 1 diabetes |
title_sort | muscle and serum myostatin expression in type 1 diabetes |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354085/ https://www.ncbi.nlm.nih.gov/pubmed/32652899 http://dx.doi.org/10.14814/phy2.14500 |
work_keys_str_mv | AT dialathang muscleandserummyostatinexpressionintype1diabetes AT monacocynthiamf muscleandserummyostatinexpressionintype1diabetes AT grafhamgracek muscleandserummyostatinexpressionintype1diabetes AT romanovanadya muscleandserummyostatinexpressionintype1diabetes AT simpsonjeremya muscleandserummyostatinexpressionintype1diabetes AT tarnopolskymarka muscleandserummyostatinexpressionintype1diabetes AT perrychristophergr muscleandserummyostatinexpressionintype1diabetes AT kalaitzoglouevangelia muscleandserummyostatinexpressionintype1diabetes AT hawkethomasj muscleandserummyostatinexpressionintype1diabetes |